SUMMARY
- Dash Bio secured $30 million in Series A funding, led by Oak HC/FT.
- Dash Bio develops automated bioanalysis infrastructure and GLP-compliant laboratory solutions to help accelerate drug development.
- The funding will expand commercial operations, increase laboratory capacity, enhance assay offerings, and strengthen the company's proprietary software platform.
Follow us
Follow usDash Bio, a Waltham, MA-based company building an infrastructure for drug development, has raised $30 million in a Series A financing round led by Oak HC/FT.
The round also saw participation from existing investors, including Freestyle Capital and Swift Ventures.
The company will use the capital to expand its commercial operations, laboratory capacity, assay offerings and proprietary software platform.
Funding Snapshot
| Metric | Details |
|---|---|
| Fundraise Amount | $30 million |
| Funding Round | Series A |
| Valuation | Undisclosed |
| Company | Dash Bio |
| Sector | Biotech / Drug Development |
| Headquarters | Waltham, Massachusetts, US |
RECOMMENDED FOR YOU
Fintech Startup Crypto.com Scores $400M Strategic Investment from Citadel Securities
Devin Jacobs
Jul 17, 2026
About Dash Bio
Founded in 2024, by Dave Johnson (CEO), Ander Tallett (COO), and Ely Porter (CSO), Dash Bio is developing infrastructure to make drug development faster more automated and more transparent.
Read More:California-Based SoundHealth Scores $12.25M in Series A Funding
The company operates a 24,000-square-foot GLP laboratory equipped with robotics, and a proprietary laboratory operating system. Its platform offers automated assay workflows covering ELISA, MSD, qPCR, ddPCR and LC-MS.
Core offerings include:
- Automated bioanalysis
- GLP compliant laboratory testing
- Digital sample tracking and traceability
- Productized assay workflows
Core Technologies / Products / Services
| Capability/Product | Application/Use Case |
|---|---|
| Automated Bioanalysis Platform | Faster preclinical sample analysis |
| Robotics | Automates laboratory workflows |
| Proprietary Lab Operating System | Digital management and workflow automation |
| ELISA, MSD, qPCR, ddPCR & LC-MS | Bioanalysis and assay testing |
Leadership Comments
“Sponsors and patients can't wait,” said Dave Johnson, Co-founder and CEO of Dash Bio. “We built Dash on a deep conviction: the pace of drug development should be set by the science, not by queues and legacy process. Our goal is to push deliverable timelines to the very limits of the underlying chemistry, physics, and biology. Everything about how we operate, from our tech-first approach to our transparent, fixed pricing, is built to serve that goal, and ultimately to get medicines to patients faster.”
“In less than two years, the Dash team has built a GLP-compliant, fully automated bioanalysis platform that the industry's largest drug developers are already adopting,” said Andy Smith, Partner at Oak HC/FT. “The team’s background architecting the digital and automation infrastructure at Moderna during one of the most consequential scale-ups in modern history brings a playbook.
Read More:California-Based Inocras Scores $31M in Series B-3 Financing
Recommended Stories for You
Startuprise Nov 6, 2025
Startuprise Nov 2, 2025
Devin Jacobs Jun 23, 2026
Devin Jacobs Apr 22, 2026
Devin Jacobs May 5, 2026
Trending Stories
Rapalogix Health Raises $20M in Series A Funding Round
Addi Raises $85M in Series D Funding Led by BTG Pactual
Venus Aerospace Raises $91M in Series B Funding Round
Comstock Appoints Former Blackstone and Citigroup Leader David Hirsh to Board of Directors
PagerDuty Appoints Eric Prengel as Chief Financial Officer
Microsoft Lays Off Xbox VP Kevin LaChapelle After 37 Years
8090 Labs Raises $135M in Series A Funding Led by Salesforce Ventures
Oratomic Raises $300M Series A funding co-led by ARCH Venture Partners
